We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Cancer Diagnostics Lab Offers Two Week Turnaround Time

By LabMedica International staff writers
Posted on 02 Sep 2015
Print article
The HiSeq 2500 advanced sequencing platform
The HiSeq 2500 advanced sequencing platform (Photo courtesy of Illumina)
An advanced cancer molecular testing laboratory can provide complete information on some 562 cancer-related genes with a turn-around time of less than two weeks.

Ashion Analytics (Phoenix, AZ, USA) a [US] Food and Drug Administration CLIA (Clinical Laboratory Improvement Amendments) certified and CAP (College of American Pathologists)-accredited molecular cancer testing laboratory is now offering its Genomic Enabled Medicine (GEM) Cancer Panel to assist doctors in treating cancer patients.

The 562 gene panel includes coding regions for 540 genes, and non-coding regions for an additional 22 genes that are known to be structurally rearranged or altered in cancer. Additional regions for the identification of specific structural variants are also included. Samples are tested at the company's Phoenix (AZ, USA) laboratory utilizing the targeted enrichment method followed by sequencing on an Illumina, Inc. (San Diego, CA, USA) HiSeq 2500 analytical instrument. The HiSeq 2500 System is a powerful and efficient ultra-high-throughput sequencing system that supports the broadest range of applications and study sizes. Results are evaluated using methods that include analysis of single nucleotide variants, insertions/deletions, structural variants, focal and whole genome copy number.

Ashion Analytics also supports research studies and clinical trials for investigators in university, hospital, and pharmaceutical industry settings with expanded whole exome sequencing with its GEM-GWTM test, which also includes analysis of copy number events and structural variation, as well as RNA sequencing.

"Our understanding of genomics today is fundamentally changing the way we view and treat cancer, and we believe the future holds even greater promise," said Dr. Michael Demeure, executive vice-president and general manager of Ashion Analytics. "As a physician who continues to treat cancer patients, I see every day the critical need to develop better diagnostics as well as new, more effective and less toxic treatment options. This unmet need drives all our efforts at Ashion Analytics."

Related Links:

Ashion Analytics 
Illumina, Inc.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.